
Opinion|Videos|February 24, 2025
Oral Systemic Treatment Options for a 28-Year-Old Woman With Moderate Atopic Dermatitis
Author(s)Raj Chovatiya, MD, PhD, MSCI
The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.
Advertisement
Episodes in this series

Video content above is provided by the following:
- Please provide your initial impressions of this case. Does the involvement of the patient’s hands influence your management plan at all?
- How would you address the patient’s concerns regarding potential adverse effects of topical corticosteroids?
- Describe your approach to treatment options for this patient. What patient-specific factors would you take into consideration when deciding on a treatment?
- In what scenarios would a JAK inhibitor be preferred over another systemic agent?
- How would decide between a topical or systemic JAK inhibitor for a patient?
- What can the patient expect in terms of efficacy and safety with upadacitinib? When should she expect initial symptom relief?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Demonstrates Positive Effects on TCS Use, Growth in Pediatric Patients
2
Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD
3
Pilot Study Tests Oral NAC as Adjunct in Vitiligo Therapy
4
Future Therapeutic Pathways and Combination Strategies in Vitiligo Management
5





















